Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Ophthalmology. 2010 Jul 29;117(11):2152–2161.e2. doi: 10.1016/j.ophtha.2010.03.031

Table 5.

Comparison of Selected Two- to Three-Year v Five-Year Outcomes among Patients with Cytomegalovirus Retinitis

Outcome 2–3-year rate 5-year rate
Mortality 12/100 PY* 9.8/100 PY
Retinitis progression
Overall 10/100 PY 7.0 /100 PY
CD4+ T cells < 50 cells/µL† 27/100 PY 23.3/100 PY
CD4+ T cells > 100 cells/µL 3/100 PY 1.8/100 PY
Visual acuity loss to
worse than 20/40
Overall 10/100 EY‡ 7.9/100 EY
CD4+ T cells < 50 cells/µL† 19/100 EY 8.8/100 EY
CD4+ T cells > 100 cells/µL 10/100 EY 5.4/100 EY
20/200 or worse
Overall 6/100 EY 3.4/100 EY
CD4+ T cells < 50 cells/µL† 7/100 EY 5.1/100 EY
CD4+ T cells > 100 cells/µL 4/100 EY 2.5/100 EY
*

PY = person-years.

†

Rates among participants with CD4+ T cells < 50 and > 100 cells/µL at enrollment.

‡

EY=eye-years.

Two-to three-year rates are from references 6,13,and 23.